𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients

✍ Scribed by José A. Lorente; Herminia Valenzuela; Juan Morote; Antoni Gelabert

Publisher
Springer
Year
1999
Tongue
English
Weight
59 KB
Volume
26
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prostate carcinoma staging: Clinical uti
Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen
✍ Juan Morote; José Antonio Lorente; Gloria Encabo 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 2 views

BACKGROUND. Biochemical markers of bone disease have been of interest as part of the investigation of prostate carcinoma and the monitoring of skeletal involvement. Bone isoenzyme of the alkaline phosphatase (BAP) is an indicator of the metabolism of the osteoblasts. An immunoradioanalyses with two

Serum prostatic acid-phosphatase levels
Serum prostatic acid-phosphatase levels in the male patients of a cancer-prevention clinic
✍ Emerson Day; Sai Hou Ying; Morton K. Schwartz; Willet F. Whitmore Jr.; Oscar Bod 📂 Article 📅 1956 🏛 John Wiley and Sons 🌐 English ⚖ 558 KB

N 1953 Fishniari arid Lernera suggested that I the inhibitory action of L-tartrate on acid phosphatase, which had been described by Abul-Fad1 and King, might be applied in the differentiation between the serum acid phosphatase of nonprostatic origin and that coming from the prostate. They devised a

Clinical features of patients who presen
Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL : The “PSA negative” patients
✍ Alison J. Birtle; Alex Freeman; John R. W. Masters; Heather A. Payne; Stephen J. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

## Background: Although < 1% of men present with prostate-specific antigen (psa)-negative prostate carcinoma, in that they have serum psa levels much lower than the tumor burden would suggest, such patients represent a management dilemma. to the authors' knowledge, little information exists in the